These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
106 related items for PubMed ID: 11387304
1. Are elevated FSH concentrations in the pre-conceptional period a risk factor for Down's syndrome pregnancies? van Montfrans JM, Lambalk CB, van Hooff MH, van Vugt JM. Hum Reprod; 2001 Jun; 16(6):1270-3. PubMed ID: 11387304 [Abstract] [Full Text] [Related]
2. Basal FSH, estradiol and inhibin B concentrations in women with a previous Down's syndrome affected pregnancy. van Montfrans JM, van Hooff MH, Martens F, Lambalk CB. Hum Reprod; 2002 Jan; 17(1):44-7. PubMed ID: 11756360 [Abstract] [Full Text] [Related]
4. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters. Wald NJ, Watt HC, Hackshaw AK. N Engl J Med; 1999 Aug 12; 341(7):461-7. PubMed ID: 10441601 [Abstract] [Full Text] [Related]
5. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy. Aitken DA, Wallace EM, Crossley JA, Swanston IA, van Pareren Y, van Maarle M, Groome NP, Macri JN, Connor JM. N Engl J Med; 1996 May 09; 334(19):1231-6. PubMed ID: 8606718 [Abstract] [Full Text] [Related]
6. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A. Haddow JE, Palomaki GE, Knight GJ, Foster DL, Neveux LM. J Med Screen; 1998 May 09; 5(3):115-9. PubMed ID: 9795869 [Abstract] [Full Text] [Related]
10. [Evaluation of a programme for the prenatal screening for Down's syndrome by ultrasonographic nuchal translucency measurement and serum determinations in the first trimester of pregnancy]. Go AT, Hupkes HW, Lomecky M, Twisk J, Blankenstein JM, van Vugt JM. Ned Tijdschr Geneeskd; 2005 Dec 10; 149(50):2795-9. PubMed ID: 16385832 [Abstract] [Full Text] [Related]
11. Antenatal screening for Down's syndrome with the quadruple test. Wald NJ, Huttly WJ, Hackshaw AK. Lancet; 2003 Mar 08; 361(9360):835-6. PubMed ID: 12642052 [Abstract] [Full Text] [Related]
12. Down's syndrome screening with nuchal translucency at 12(+0)-14(+0) weeks and maternal serum markers at 14(+1)-17(+0) weeks: a prospective study. Rozenberg P, Malagrida L, Cuckle H, Durand-Zaleski I, Nisand I, Audibert F, Benattar C, Tribalat S, Cartron M, Lemarié P, Stoessel J, Capolagui P, Jansé-Marec J, Barbier D, Allouch C, Perdu M, Roberto A, Lahna Z, Giudicelli Y, Ville Y. Hum Reprod; 2002 Apr 08; 17(4):1093-8. PubMed ID: 11925411 [Abstract] [Full Text] [Related]
13. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening. Tsai MS, Huang YY, Hwa KY, Cheng CC, Lee FK. J Formos Med Assoc; 2001 May 08; 100(5):319-25. PubMed ID: 11432311 [Abstract] [Full Text] [Related]
14. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening. Haddow JE, Palomaki GE, Knight GJ, Cunningham GC, Lustig LS, Boyd PA. N Engl J Med; 1994 Apr 21; 330(16):1114-8. PubMed ID: 7510852 [Abstract] [Full Text] [Related]
15. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases. Marsk A, Grunewald C, Saltvedt S, Valentin L, Almström H. Acta Obstet Gynecol Scand; 2006 Apr 21; 85(5):534-8. PubMed ID: 16752230 [Abstract] [Full Text] [Related]
16. Increased time-to-pregnancy and first trimester Down's syndrome screening. Ranta JK, Raatikainen K, Romppanen J, Pulkki K, Heinonen S. Hum Reprod; 2010 Feb 21; 25(2):412-7. PubMed ID: 19945962 [Abstract] [Full Text] [Related]